Abstract
Background Introduction of the monoclonal antibody rituximab to chemotherapy regimens has substantially improved disease-free and overall survival in patients with non-Hodgkin lymphomas (NHL). The short-term safety of this drug has been widely reported, but there are few data on long-term safety, which suggests that these patients require prolonged follow-up. Aim of the review To review the literature on follow-up models, with a focus on the safety of rituximab therapy for diffuse large B-cell lymphoma and follicular lymphoma. Method The Cochrane Library, Embassy, Lilacs, Medline, and Scirus databases were searched for systematic reviews and randomized controlled trials. Furthermore, textbooks and journals on pharmaceutical care and institutional websites were searched for patient management recommendations. The outcomes were follow-up models and grade 3, 4, and 5 adverse reactions. Results Five systematic reviews and eight clinical trials or updates describing patient follow-up or reporting adverse reactions were identified. Only one systematic review and seven clinical trials reported follow-up routines for patients receiving rituximab, including information on staging, frequency of reassessment, and laboratory tests, as well as pre-infusion care and management of acute or delayed adverse reactions. Five systematic reviews and four clinical trials reported data on statistically significant adverse reactions (fever, leukopenia, infection). Four guidelines or institutional protocols for treatment and follow-up were identified, as well as seven studies describing experiences in the implementation of pharmaceutical care for oncology patients, but none were specifically focused on follow-up of patients receiving rituximab for NHL. Conclusion Although some systematic reviews and clinical trials contain guidance on follow-up of patients receiving rituximab for NHL, there are no validated strategies for systematic follow-up of these patients with a focus on safety. As there are few data on long-term safety profile of these novel treatments, monitoring strategies should be developed and implemented to ensure safe and optimized use of drugs recently added to the therapeutic arsenal of clinical oncology.
Similar content being viewed by others
References
Australian Cancer Network Diagnosis and Management of Lymphoma Guidelines Working Party. Guidelines for the diagnosis and management of lymphoma. Sydney: The Cancer Council Australia and Australian Cancer Network; 2005.
Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Byrd JC, Czuczman MS, et al. NCCN Clinical Practice Guidelines in oncology: non-Hodgkin’s lymphomas. J Natl Compr Canc Netw. 2010;8(3):288–334.
Rituximabe no tratamento do linfoma difuso de grandes células B [Rituximab in the treatment of diffuse large B cell lymphoma]. Brazilian Bulletin on Health Technology Assessment (BRATS) [serial on the Internet]. 2009;4(10); Available from: http://200.214.130.94/rebrats/brats.php.
Cheung MC, Haynes AE, Meyer RM, Stevens A, Imrie KR. Rituximab in lymphoma: a systematic review and consensus practice guideline from Cancer Care Ontario. Cancer Treat Rev. 2007;33(2):161–76.
Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(19):3121–7.
Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105(4):1417–23.
Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–42.
Freedman A, Friedberg J. Initial treatment of follicular lymphoma. 2013 [cited 2013 03/31/2013]; Available from: http://www.uptodate.com.
Ghielmini M, Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule. Blood. 2004;103(12):4416–23.
Knight C, Hind D, Brewer N, Abbott V. Rituximab (MabThera) for aggressive non-Hodgkin’s lymphoma: systematic review and economic evaluation. Health Technol Assess. 2004;8(37):iii, ix–xi, 1–82.
van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006;108(10):3295–301.
Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin’s lymphoma. N Engl J Med. 2008;359(6):613–26.
MabThera® (rituximab). F. Hoffmann-La Roche; 2013 [cited 2013 03/31/2013]; Available from: http://www.dialogoroche.com.br/content/dam/dialogo/pt_br/Bulas/M/MabThera/mabthera-profissional-20120119.pdf.
van Oers MH, Van Glabbeke M, Giurgea L, Klasa R, Marcus RE, Wolf M, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin’s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. 2010;28(17):2853–8.
Ivama A, Noblat L, de Castro M, de Oliveira N, Jaramillo N, Rech N. Consenso Brasileiro de Atenção Farmacêutica [Brazilian Consensus on Pharmaceutical Care]. 1st ed. Brasília: Organização Pan-Americana da Saúde; 2002.
Jaehde U, Liekweg A, Simons S, Westfeld M. Minimising treatment-associated risks in systemic cancer therapy. Pharm World Sci. 2008;30(2):161–8.
Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990;47(3):533–43.
Gao G, Liang X, Jiang J, Zhou X, Huang R, Chu Z, et al. A systematic review and meta-analysis of immunochemotherapy with rituximab for B-cell non-Hodgkin’s lymphoma. Acta Oncol. 2010;49(1):3–12.
Schulz H, Bohlius J, Skoetz N, Trelle S, Kober T, Reiser M, Dreyling M, Herold M, Schwarzer G, Hallek M, Engert A. Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin’s lymphoma. Cochrane Database Syst Rev. 2007;(4). doi:10.1002/14651858.CD003805.pub2.
Rafailidis PI, Kakisi OK, Vardakas K, Falagas ME. Infectious complications of monoclonal antibodies used in cancer therapy: a systematic review of the evidence from randomized controlled trials. Cancer. 2007;109(11):2182–9.
Vidal L, Gafter-Gvili A, Leibovici L, Shpilberg O. Rituximab as maintenance therapy for patients with follicular lymphoma. Cochrane Database Syst Rev. 2009;(2). doi:10.1002/14651858.CD006552.pub2.
Martí-Carvajal AJ, Cardona AF, Lawrence A. Interventions for previously untreated patients with AIDS-associated non-Hodgkin’s lymphoma. Cochrane Database Syst Rev. 2009;(3):CD005419.
Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010;116(12):2040–5.
Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 2005;23(18):4117–26.
Kaplan LD, Lee JY, Ambinder RF, Sparano JA, Cesarman E, Chadburn A, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood. 2005;106(5):1538–43.
Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9(2):105–16.
CHOP-R. Ontario: Juravinski Cancer Centre; 2008 [cited 2013 03/12/2013]; Available from: http://www.jcc.hhsc.ca/workfiles/PHARMACY/HE-CHOP-R.pdf.
Non-Hodgkin’s Lymphomas. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Version 1.2013 ed: National Comprehensive Cancer Network; 2012.
Guidance on the administration of rituximab infusions. London: The North London Cancer Network; 2009 [cited 2013 03/31/2013]; Available from: http://www.nlcn.nhs.uk/BChemoGui.
Guidelines for the management of tumour lysis syndrome. London: The North London Cancer Network; 2010 [cited 2013 03/31/2013]; Available from: http://www.nlcn.nhs.uk/BChemoGui.
Broadfield L. Pharmaceutical care in oncology pharmacy practice: a method for using outcome indicators. J Oncol Pharm Pract. 1995;1(1):9–14.
Cavero Rodrigo E, Climente Martí M, Navarro Fontestad MC, Jiménez Torres NV. Quality assessment of two pharmaceutical care models for onco-haematological patients. Farm Hosp. 2007;31(4):231–7.
Wong S, Gray E. Clinical pharmacy services in oncology clinics. J Oncol Pharm Pract. 1999;5(1):49–54.
Knez L, Laaksonen R, Duggan C. Evaluation of clinical interventions made by pharmacists in chemotherapy preparation. Radiol Oncol. 2010;44(4):249–56.
Serrano-Fabiá A, Cavero Rodrigo E, Albert Marí A, Almenar Cubells D, Jiménez Torres NV. Pharmaceutical validation as a process of improving the quality of antineoplastic treatment. J Oncol Pharm Pract. 2005;11(2):45–50.
Serrano-Fabiá A, Albert-Marí A, Almenar-Cubells D, Jiménez-Torres NV. Multidisciplinary system for detecting medication errors in antineoplastic chemotherapy. J Oncol Pharm Pract. 2010;16(2):105–12.
Bremberg E, Hising C, Nylen U, Ehrsson H, Eksborg S. An evaluation of pharmacist contribution to an oncology ward in a Swedish hospital. J Oncol Pharm Pract. 2006;12(2):75–81.
Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24(19):3187–205.
Eisenach M. Pharmaceutical counseling. In: Pharmacy GSoO, editor. QuapoS 4: quality standard for the oncology pharmacy service with commentary. Hamburg: European Society of Oncology Pharmacy (ESOP); 2009. p. 452.
Castro M, Fuchs F, Ferreira M. Reflexão sobre a prática e o ensino do seguimento farmacoterapêutico de pacientes [Reflection on the practice and teaching of patients pharmacotherapeutic follow-up]. In: Storpirtis S, Mori A, Yochiy A, Ribeiro E, Porta V, editors. Farmácia Clínica e Atenção Farmacêutica [Clinical pharmacy and pharmaceutical care]. Rio de Janeiro: Guanabara Koogan; 2008.
Witzel M. Aspectos conceituais e filosóficos da Assistência Farmacêutica, Farmácia Clínica e Atenção Farmacêutica [Conceptual and philosophical aspects of pharmaceutical services, clinical pharmacy and pharmaceutical care]. In: Storpirtis S, Mori A, Yochiy A, Ribeiro E, Porta V, editors. Farmácia Clínica e Atenção Farmacêutica [Clinical pharmacy and pharmaceutical care]. Rio de Janeiro: Guanabara Koogan; 2008.
Simons S, Ringsdorf S, Braun M, Mey UJ, Schwindt PF, Ko YD, et al. Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care. Support Care Cancer. 2011;19(7):1009–18.
Moreira R. Suggesting pharmacotherapeutical follow-up in chronic myeloid leukemia: a methodological approach model. Braz J Oncol. 2009;55(4):375–8.
Omoti C, Agada L. Compliance with chemotherapy in adult leukemia patients in Benin City, Nigeria. Seguimiento Farmacoterapéutico. 2005;3(1):1–9.
Eliasson L, Clifford S, Barber N, Marin D. Exploring chronic myeloid leukemia patients’ reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res. 2011;35(5):626–30.
Denois V, Nourissat A, Jacquin J, Guastalla J, Chauvin F. Adherence with oral chemotherapy: results from a qualitative study of the behaviour and representations of patients and oncologists. Eur J Cancer Care. 2011;20(4):520–7.
Oakley C. Developing an intervention for cancer patients prescribed oral chemotherapy: a generic patient diary. Eur J Cancer Care. 2010;19(1):21–8.
Williamson S. Management of oral anticancer therapies. Pharm J. 2008;281(7522):399–402.
Forster AJ, Halil RB, Tierney MG. Pharmacist surveillance of adverse drug events. Am J Health Syst Pharm. 2004;61(14):1466–72.
Winterstein AG, Hatton RC, Gonzalez-Rothi R, Johns TE, Segal R. Identifying clinically significant preventable adverse drug events through a hospital’s database of adverse drug reaction reports. Am J Health Syst Pharm. 2002;59(18):1742–9.
Roscoe J, Goransson E, Slancar M, Smith J, Taylor S, Tyson S. A multidisciplinary approach to ensure safety in the prescribing and administration of chemotherapy. J Oncol Pharm Pract. 2000;6(2):60–3.
Acknowledgments
To the care team oncology and hematology at the Hospital Nossa Senhora da Conceição, Grupo Hospitalar Conceição, Ministry of Health, Brazil.
Funding
Brazilian National Health Surveillance Agency (Anvisa).
Conflicts of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hegele, V., Stoll, P., Wüst, D. et al. Pharmaceutical follow-up for patients on rituximab therapy for non-Hodgkin lymphoma: what is the evidence?. Int J Clin Pharm 35, 513–519 (2013). https://doi.org/10.1007/s11096-013-9780-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11096-013-9780-1